Stoke Therapeutics (NASDAQ:STOK) Insider Sells 5,545 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 5,545 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $30.67, for a total transaction of $170,065.15. Following the transaction, the insider owned 20,110 shares in the company, valued at approximately $616,773.70. The trade was a 21.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Barry Ticho also recently made the following trade(s):

• On Tuesday, August 18th, Barry Ticho sold 4,767 shares of Stoke Therapeutics stock. The shares were sold at an average price of $32.03, for a total transaction of $152,687.01.
• On Monday, August 3rd, Barry Ticho sold 7,176 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.04, for a total value of $208,391.04.

Stoke Therapeutics Price Performance

NASDAQ:STOK traded down $0.51 during trading hours on Thursday, reaching $29.99. 510,577 shares of the company were exchanged, compared to its average volume of 763,995. The business has a 50 day moving average of $31.23 and a 200 day moving average of $32.23. Stoke Therapeutics, Inc. has a 1-year low of $18.80 and a 1-year high of $40.22. The company has a market capitalization of $1.94 billion, a P/E ratio of -8.98 and a beta of 1.23.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). The company had revenue of $9.32 million for the quarter, compared to the consensus estimate of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. As a group, equities research analysts anticipate that Stoke Therapeutics, Inc. will post -3.52 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Canaccord Genuity Group reduced their price objective on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th. JPMorgan Chase & Co. assumed coverage on shares of Stoke Therapeutics in a report on Friday, August 21st. They set an “overweight” rating and a $40.00 price target for the company. Guggenheim reiterated a “buy” rating and set a $60.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. The Goldman Sachs Group assumed coverage on shares of Stoke Therapeutics in a research note on Monday, July 13th. They issued a “buy” rating and a $44.00 price objective on the stock. Finally, BTIG Research restated a “buy” rating and set a $39.00 price objective on shares of Stoke Therapeutics in a research report on Monday, May 11th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $44.25.

Institutional Investors Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Kestra Advisory Services LLC acquired a new stake in Stoke Therapeutics in the fourth quarter valued at $26,000. Quantbot Technologies LP acquired a new position in Stoke Therapeutics during the 2nd quarter worth about $34,000. KBC Group NV acquired a new position in Stoke Therapeutics during the 1st quarter worth about $36,000. Harbour Investments Inc. grew its position in shares of Stoke Therapeutics by 312.9% in the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after buying an additional 898 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its position in shares of Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after buying an additional 1,668 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.